The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia

BACKGROUND: Elevated serum fibroblast growth factor 23 (FGF23) is strongly associated with cardiovascular risk and mortality. Tenapanor, an inhibitor of gastrointestinal sodium/hydrogen exchanger isoform 3, decreased serum phosphate in a randomized, double-blind, placebo-controlled Phase 2 trial (Cl...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Nephrol Dial Transplant
Main Authors: Block, Geoffrey A, Rosenbaum, David P, Yan, Andrew, Greasley, Peter J, Chertow, Glenn M, Wolf, Myles
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6365767/
https://ncbi.nlm.nih.gov/pubmed/29617976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfy061
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki